Funding Support and Author Disclosures Dr Sonbol has received consulting fees from Novartis (to self) and Boehringer Ingelheim (to his institution); has received institutional research support from Taiho and Eli Lilly. Dr Bekaii-Saab has received institutional research funding from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS; has received consulting fees (to his institution) from Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA, and Merck, and (to self) from Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, Elevar, Illumina, Foundation Medicine, Sanofi, Glaxo SmithKline, and Xilio; has served on independent data monitoring committees or data safety monitoring boards for The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan, and 1Globe; has served on scientific advisory boards for Imugene, Immuneering, Xilis, Replimune, Artiva, and Sun Biopharma; has received royalties from UpToDate; and holds patents licensed to Imugene and Recursion. Dr Larsen has reported that she has no relationships relevant to the contents of this paper to disclose.